Since the percentage of angiotensin II- and/or ACTH-responsive adenomas may vary by region and patient background among various centers, we think that it would be necessary to analyze a large number of patients from different geographical areas to establish the usefulness of simple standing test in clinical practice. This evidence concerns the gene AGT and adenoma.